ESMO 2022: Sacituzumab Govitecan-hziy shows promising efficacy in HER2-low-expression/HER2-0 metastatic breast cancer (TROPiCS-02 study)

Breast cancer is the second leading cause of cancer death in women, with HR+/HER2- being the most common classification, accounting for about 70%

Sacituzumab Govitecan-hziy (gosartozumab) is a pioneering ADC drug

The TROPiCS-02 study is a Phase III clinical trial designed to evaluate the efficacy and safety

See: ASCO2022 | TROPiCS-02 Clinical Blockbuster Release: Gosartolizumab Reduces HR+/HER2-MBC Progression or Death by 34%!

Presented at the ESMO 2022 meeting, Sacituzumab Govitecan-hziy (Trodelvy) improved progression-free survival (PFS) and overall response rate (ORR) in patients with HER2 low expression in hormone receptor-positive metastatic breast cancer with a her2 low expression or HER2 immunohistochemical test result of zero (IHC0).

Introducing the findings during the ESMO2022 conference, Dr Frederik Marmé of the University of Mannheim in Germany said: "HER2 low expression is a relatively newly defined subgroup of negative patients, accounting for about 65% of

Median PFS in patients with HER2 low expression disorders assigned to the sacituzumab govitecan group was superior to physician-selected treatment (6.

"This study shows that sacituzumab govitecan improves efficacy outcomes

The TROPiCS-02 trial enrolled 543 patients

For this retrospective subgroup analysis, investigators evaluated local IHC and in situ hybridization to determine efficacy

52% of patients had HER2 low expression, of which 149 were assigned to the sacituzumab govitecan group and 134 to the doctor-selected treatment group

In populations with low HER2 expression (26% vs 12%; Odds ratio [OR], 2.

The median duration of remission (DOR) was 7.

Marmé said: "The safety characteristics of sacituzumab govitecan in the HER2 low expression and HER2 zero expression subgroups were substantially consistent

Professor Shym Goel of Peter MacCallum Cancer Center offered an insight into the findings